Johnson and Johnson Quote - JNJ

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

20.70

Bid

20.00

Offer

21.57

Volume

5,141

20.35 Day's Range 20.73

0.00 52 Week Range 0.00

Previous Close

20.38

Open

20.35

Last Trade

200

20.7

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting PR Newswire RARITAN, N.J., Nov. 19, 2024 More...

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results PR Newswire SPRING HOUSE, Pa...

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study PR Newswire WASHINGTON, Nov. 14, 2024 Adults with...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease PR...

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma PR...

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR Newswire SPRING HOUSE, Pa., Nov. 7, 2024 New data for investigational nipocalimab in...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IFSSInterfield Global Software Inc	$ 0.055 (37.50%)	362k
MOLYGreenland Resources Inc	$ 0.89 (9.88%)	171.9k
INXDINX Digital Company Inc	$ 0.065 (8.33%)	34.44k
DEERDeere CDR	$ 23.27 (7.83%)	15.34k
ZEFIZefiro Methane Corp	$ 0.83 (7.79%)	297.05k
BMNDBiomind Labs Inc	$ 0.31 (-47.46%)	1.5k
LITSLithos Energy Ltd	$ 0.045 (-18.18%)	271.66k
FHFilament Health Corp	$ 0.035 (-12.50%)	17.83k
CYBNCybin Inc	$ 14.15 (-9.12%)	32.8k
GRAMGold Flora Corporation	$ 0.055 (-8.33%)	158.18k
DEFIValour Inc	$ 3.38 (7.30%)	1.94M
CBSTCannabist Company Holdings Inc	$ 0.15 (0.00%)	539.99k
IFSSInterfield Global Software Inc	$ 0.055 (37.50%)	362k
VRNOVerano Holdings Corp	$ 2.14 (-7.76%)	359.91k
BTQBTQ Technologies Corp	$ 0.29 (-6.45%)	316.83k